The best of artificial intelligence in 2024
Post written by Michael B. Wallace, MD, MPH, GIE Editor Emeritus from the Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA. This was an invited review article commissioned by the GIE…
Related Articles
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Durvalumab plus bevacizumab plus TACE has the potential to set a new standard of care. With additional follow-up of the EMERALD-1 study, future analyses, including…
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
TACE plus lenvatinib plus pembrolizumab showed significant, clinically meaningful improvement in progression-free survival in patients with unresectable, non-metastatic hepatocellular carcinoma compared with TACE plus placebo.…
Endoscopic vacuum therapy for the treatment of Boerhaave syndrome: a multicenter analysis
Boerhaave syndrome, an effort rupture of the esophagus, is a rare but serious condition. Endoscopic vacuum therapy (EVT) is a new therapeutic approach for GI…
With AI Assistance in Colonoscopy, Benign Lesions More Often Removed
Colonoscopies assisted by AI technology are significantly more likely to result in the resection of benign lesions only.
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Immune checkpoint inhibitors (ICI) have led to breakthrough improvements in the management of malignancy including hepatocellular (HCC) and biliary tract cancer, improving decades-old standards of…
Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need…
Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a wide spectrum of liver injuries, ranging from hepatic steatosis, metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis to MASLD-associated…
World Gastroenterology Organisation (WGO) News and Events : Journal of Clinical Gastroenterology
An abstract is unavailable.
Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Efficacy and Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and a 5-year survival rate of just 12.8%.1 Early diagnosis is rare,…
